<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483560</url>
  </required_header>
  <id_info>
    <org_study_id>GN10DI406</org_study_id>
    <secondary_id>2011-000300-18</secondary_id>
    <nct_id>NCT01483560</nct_id>
  </id_info>
  <brief_title>REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)</brief_title>
  <acronym>REMOVAL</acronym>
  <official_title>Phase 3 Study of Metformin in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Serono S.A., Geneva</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Itamar-Medical, Israel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Melbourne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the
      Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated
      insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured
      by progression of carotid intima-media thickness (cIMT), in adults with confirmed type 1
      diabetes aged 40 years and over at increased risk for cardiovascular disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 18, 2017</completion_date>
  <primary_completion_date type="Actual">March 19, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)</measure>
    <time_frame>0, 12 months, 24 months, 36 months</time_frame>
    <description>Progression of averaged mean far wall common carotid artery intima media thickness IMT (mean cIMT) measured using B mode ultrasonography with a 7.0 MHz or higher broadband linear array transducer and concurrent recording of 3-lead electrocardiogram (ECG). Longitudinal images of the common carotid artery will be obtained at anterior, lateral and posterior angles at baseline, 12, 24 and 36 months using Meijer's arc to standardize the transducer angle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Baseline, Year 3</time_frame>
    <description>Measured in accredited local laboratories participating in DCCT-aligned quality control programmes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL Cholesterol</measure>
    <time_frame>Baseline, Year 3</time_frame>
    <description>mmol/L Centrally assayed at the University of Glasgow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Estimated Glomerular Filtration Rate</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Number of participants developing new microalbuminuria; change in absolute concentration Calculated using the MDRD equation1 based on creatinine measured in accredited local laboratories</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Retinopathy and at Least a 2 Stage Progression in Retinopathy From Baseline to 36 Months</measure>
    <time_frame>Baseline, Year 3</time_frame>
    <description>Two color 45Â° field retinal photographs (fields 1 and 2) from each eye at 0 and 36 months graded at the University of Wisconsin Ocular Epidemiology Reading Center (OERC) using the modified Airlie House classification scheme and the Early Treatment Diabetic Retinopathy Severity scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Weight</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Measured at sites using calibrated weighing scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin Dose</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
    <description>Units/ kg body weight Extracted by study nurses from the Study Diary and reported on the study CRF using dedicated fields</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Endothelial Function</measure>
    <time_frame>Baseline, Year 1, Year 3</time_frame>
    <description>In some centres (Arbitrary units) Reactive Hyperaemia Index using the ENDOPAT device (Itamar, Israel)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">493</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>3 years treatment duration</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 years duration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 Diabetes for five years or more*

          -  Age 40 years or above

          -  7.0 =&lt; HbA1c &lt;10.0% (53 - 86 mmol/mol)

        AND 3 or more of the following ten CardioVascular Disease (CVD) risk factors:

          -  BMI &gt;27 kg/m^2

          -  Current HbA1c &gt;8.0% (64 mmol/mol)

          -  Known CVD/peripheral vascular disease

          -  Current smoker

          -  Estimated glomerular filtration rate (eGFR) &lt;90 ml/min per 1.73 m^3

          -  Confirmed micro- or macroalbuminuria [according to local assays and reference ranges]

          -  Hypertension (BP &gt;=140/90 millimeters of mercury (mmHg) or established on
             antihypertensive treatment)

          -  Dyslipidaemia [total cholesterol &gt;=5.0 mmol/L (200 mg/dL);OR HDL cholesterol &lt;1.20
             mmol/L (46mg/dL) [MEN]; OR &lt;1.30 mmol/L (50 mg/dL) [WOMEN]; or triglycerides &gt;=1.7
             mmol/L (150mg/dL); or established on lipid-lowering treatment)]

          -  Strong family history of CVD (at least one parent, biological aunt/ uncle, or sibling
             with myocardial infarction or stroke aged &lt;60 years)

          -  Duration of diabetes &gt; 20 years

        Exclusion Criteria:

          -  eGFR &lt; 45 ml/min/1.73m2

          -  woman of childbearing age not on effective contraception

          -  Pregnancy and/or lactation

          -  Acute coronary syndrome or Stroke/Transient Ischaemic Attack within the last three
             months

          -  NYHA stage 3 or 4 heart failure

          -  Significant hypoglycaemia unawareness

          -  Impaired cognitive function/ unable to give informed consent

          -  Previous carotid surgery/ inability to capture adequate carotid images

          -  Estimated glomerular filtration &lt; 45ml/min/1.73m^2 (MDRD)

          -  Gastroparesis

          -  History of lactic acidosis

          -  Other contraindications to metformin (hepatic impairment, known hypersensitivity to
             metformin, acute illness such as dehydration, severe infection, shock, acute cardiac
             failure or suspected tissue hypoxia)

          -  Any coexistent life threatening condition including prior diagnosis of cancer within
             two years

          -  History of alcohol problem or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Petrie, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helen Colhoun, Prof</last_name>
    <role>Study Director</role>
    <affiliation>University of Dundee</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Albert Hospital</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Health Care</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa Hospital Riverside Campus</name>
      <address>
        <city>Ottawa</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steno Diabetes Centre</name>
      <address>
        <city>Gentofte</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayr Hospital</name>
      <address>
        <city>Ayr</city>
        <zip>KA6 6DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Support Unit, Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital North Durham</name>
      <address>
        <city>Durham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edinburgh Western Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peninsula NIHR Clinical Research Facility, Royal Devon and Exeter NHS Foundation Trust</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stobhill Hospital, Diabetes Clinic</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucestershire Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <zip>GL1 3NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael White Diabetes Centre, Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Sciences Centre, University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Unit, International Centre for Circulatory Health, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellcome Trust Clinical Research Facility, Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle NIHR Clinical Research Facility, Royal Victoria Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diabetes Clinical Research Centre, Plymouth</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 23, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <results_first_submitted>September 20, 2018</results_first_submitted>
  <results_first_submitted_qc>February 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 3, 2019</results_first_posted>
  <last_update_submitted>June 4, 2019</last_update_submitted>
  <last_update_submitted_qc>June 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Glasgow</investigator_affiliation>
    <investigator_full_name>Prof John Petrie</investigator_full_name>
    <investigator_title>Clinical Professor in Diabetic Medicine</investigator_title>
  </responsible_party>
  <keyword>REMOVAL</keyword>
  <keyword>metformin</keyword>
  <keyword>carotid IMT</keyword>
  <keyword>LDL Cholesterol</keyword>
  <keyword>endothelial function</keyword>
  <keyword>retinopathy</keyword>
  <keyword>HbA1c</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Site specific participant data will be made available to the site PIs later in 2017, after the main publications.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 9, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT01483560/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/60/NCT01483560/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>493 participants where enrolled and consented. All participants entered a 3 month Run In phase with placebo. Participants who remained eligible were randomly assigned to receive metformin or placebo for 3 years. 65 participants where ineligible to be randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin</title>
          <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="219"/>
                <participants group_id="P2" count="209"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="193"/>
                <participants group_id="P2" count="194"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin</title>
          <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="219"/>
            <count group_id="B2" value="209"/>
            <count group_id="B3" value="428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                    <measurement group_id="B2" value="209"/>
                    <measurement group_id="B3" value="428"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="8.5"/>
                    <measurement group_id="B2" value="55.8" spread="8.8"/>
                    <measurement group_id="B3" value="55.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Diagnosis Duration</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.4" spread="11"/>
                    <measurement group_id="B2" value="34.3" spread="10.5"/>
                    <measurement group_id="B3" value="33.85" spread="10.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Existing Cardiovascular Disease</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HbA1c</title>
          <units>mmol/mol</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.8"/>
                    <measurement group_id="B2" value="64.7"/>
                    <measurement group_id="B3" value="64.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Daily Insulin Dose</title>
          <units>units/kg</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.63"/>
                    <measurement group_id="B2" value="0.68"/>
                    <measurement group_id="B3" value="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.4" spread="4.5"/>
                    <measurement group_id="B2" value="28.5" spread="4.1"/>
                    <measurement group_id="B3" value="28.5" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure</title>
          <units>Systolic BP (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.5" spread="15"/>
                    <measurement group_id="B2" value="128.5" spread="14.6"/>
                    <measurement group_id="B3" value="129.5" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4" spread="0.88"/>
                    <measurement group_id="B2" value="4" spread="0.93"/>
                    <measurement group_id="B3" value="4" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>eGFR</title>
          <units>ml/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.9" spread="20.9"/>
                    <measurement group_id="B2" value="91.1" spread="21.6"/>
                    <measurement group_id="B3" value="92" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetic Retinopathy</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="219"/>
                    <count group_id="B2" value="209"/>
                    <count group_id="B3" value="428"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)</title>
        <description>Progression of averaged mean far wall common carotid artery intima media thickness IMT (mean cIMT) measured using B mode ultrasonography with a 7.0 MHz or higher broadband linear array transducer and concurrent recording of 3-lead electrocardiogram (ECG). Longitudinal images of the common carotid artery will be obtained at anterior, lateral and posterior angles at baseline, 12, 24 and 36 months using Meijer's arc to standardize the transducer angle.</description>
        <time_frame>0, 12 months, 24 months, 36 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Averaged Mean Far Wall Common Carotid Artery Intima-media Thickness (cIMT)</title>
          <description>Progression of averaged mean far wall common carotid artery intima media thickness IMT (mean cIMT) measured using B mode ultrasonography with a 7.0 MHz or higher broadband linear array transducer and concurrent recording of 3-lead electrocardiogram (ECG). Longitudinal images of the common carotid artery will be obtained at anterior, lateral and posterior angles at baseline, 12, 24 and 36 months using Meijer's arc to standardize the transducer angle.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.773" spread="0.14"/>
                    <measurement group_id="O2" value="0.791" spread="0.183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.782" spread="0.147"/>
                    <measurement group_id="O2" value="0.788" spread="0.174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.792" spread="0.145"/>
                    <measurement group_id="O2" value="0.823" spread="0.187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.793" spread="0.134"/>
                    <measurement group_id="O2" value="0.820" spread="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c</title>
        <description>Measured in accredited local laboratories participating in DCCT-aligned quality control programmes.</description>
        <time_frame>Baseline, Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c</title>
          <description>Measured in accredited local laboratories participating in DCCT-aligned quality control programmes.</description>
          <units>%units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="0.9"/>
                    <measurement group_id="O2" value="8.0" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="0.9"/>
                    <measurement group_id="O2" value="8.1" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in LDL Cholesterol</title>
        <description>mmol/L Centrally assayed at the University of Glasgow</description>
        <time_frame>Baseline, Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in LDL Cholesterol</title>
          <description>mmol/L Centrally assayed at the University of Glasgow</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="0.7"/>
                    <measurement group_id="O2" value="2.25" spread="0.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="0.83"/>
                    <measurement group_id="O2" value="2.21" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Estimated Glomerular Filtration Rate</title>
        <description>Number of participants developing new microalbuminuria; change in absolute concentration Calculated using the MDRD equation1 based on creatinine measured in accredited local laboratories</description>
        <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Estimated Glomerular Filtration Rate</title>
          <description>Number of participants developing new microalbuminuria; change in absolute concentration Calculated using the MDRD equation1 based on creatinine measured in accredited local laboratories</description>
          <units>ml/min/1.73m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9" spread="20.9"/>
                    <measurement group_id="O2" value="91.1" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.1" spread="20.8"/>
                    <measurement group_id="O2" value="87.2" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Retinopathy and at Least a 2 Stage Progression in Retinopathy From Baseline to 36 Months</title>
        <description>Two color 45Â° field retinal photographs (fields 1 and 2) from each eye at 0 and 36 months graded at the University of Wisconsin Ocular Epidemiology Reading Center (OERC) using the modified Airlie House classification scheme and the Early Treatment Diabetic Retinopathy Severity scale.</description>
        <time_frame>Baseline, Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Retinopathy and at Least a 2 Stage Progression in Retinopathy From Baseline to 36 Months</title>
          <description>Two color 45Â° field retinal photographs (fields 1 and 2) from each eye at 0 and 36 months graded at the University of Wisconsin Ocular Epidemiology Reading Center (OERC) using the modified Airlie House classification scheme and the Early Treatment Diabetic Retinopathy Severity scale.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
                <count group_id="O2" value="209"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="191"/>
                    <measurement group_id="O2" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Weight</title>
        <description>Measured at sites using calibrated weighing scales</description>
        <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Weight</title>
          <description>Measured at sites using calibrated weighing scales</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.9" spread="15.4"/>
                    <measurement group_id="O2" value="83.5" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" spread="15.4"/>
                    <measurement group_id="O2" value="83.2" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin Dose</title>
        <description>Units/ kg body weight Extracted by study nurses from the Study Diary and reported on the study CRF using dedicated fields</description>
        <time_frame>Baseline, Year 1, Year 2, Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin Dose</title>
          <description>Units/ kg body weight Extracted by study nurses from the Study Diary and reported on the study CRF using dedicated fields</description>
          <units>units/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.26"/>
                    <measurement group_id="O2" value="0.68" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="0.26"/>
                    <measurement group_id="O2" value="0.67" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Endothelial Function</title>
        <description>In some centres (Arbitrary units) Reactive Hyperaemia Index using the ENDOPAT device (Itamar, Israel)</description>
        <time_frame>Baseline, Year 1, Year 3</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metformin</title>
            <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Endothelial Function</title>
          <description>In some centres (Arbitrary units) Reactive Hyperaemia Index using the ENDOPAT device (Itamar, Israel)</description>
          <units>RHI (Arbitrary units)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="194"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="0.74"/>
                    <measurement group_id="O2" value="2.24" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="0.69"/>
                    <measurement group_id="O2" value="2.24" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data collected from the date of consent until 30 days post last IMP dose, an average of 3 years.</time_frame>
      <desc>Definition used same as clinical trials.gov</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin</title>
          <description>Oral Metformin (as Glucophage 500mg x 2 bd) titrated from initial 500mg to target 2000mg daily
Metformin: 3 years treatment duration 219 of 428 randomised were assigned to Metformin Group</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 3 years duration 209 of the 428 randomised were assigned to Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="219"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune System Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="219"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="219"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Angiogram</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Blood Glucose Fluctuation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolic and nutrition</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="219"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="219"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>hypoglycaemic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Coronary artery bypass graft</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>lung lobectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>coronary stent insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Amputation revision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Surgery (unspecified)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Spinal fusion Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Aortic valve repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Ischaemic Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="112" subjects_at_risk="219"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="219"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Opthalmic adverse events</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="219"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="88" subjects_affected="88" subjects_at_risk="219"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="219"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity to Metformin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="219"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="209"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof John Petrie</name_or_title>
      <organization>University of Glasgow</organization>
      <phone>+44 141 330 ext 3325</phone>
      <email>John.Petrie@glasgow.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

